PURPOSE We performed an open-label randomized controlled phase III study comparing
treatment outcome and toxicity between radiotherapy (RT) with concomitant cisplatin versus …

PURPOSE: No randomized trials have been conducted to directly compare radiotherapy
(RT) with concomitant cisplatin (CDDP) versus concomitant cetuximab (CTX) as first-line …

English Purpose To investigate the effect of adding concurrent chemotherapy (CT) to
cetuximab plus radiotherapy (RT; CT-cetux-RT) compared with cetuximab plus RT (cetux …

Background We conducted a multinational, randomized study to compare radiotherapy
alone with radiotherapy plus cetuximab, a monoclonal antibody against the epidermal …

Purpose Cetuximab is a chimeric monoclonal antibody that targets the epidermal growth
factor receptor. Cetuximab has activity in squamous cell carcinoma and enhances both …

PURPOSE: The addition of platinum-based chemotherapy (ChRT) or cetuximab (ExRT) to
concurrent radiotherapy (RT) has resulted in improved survival in Phase III studies for …

Purpose Combining cisplatin or cetuximab with radiation improves overall survival (OS) of
patients with stage III or IV head and neck carcinoma (HNC). Cetuximab plus platinum …

Both concurrent chemoradiotherapy (CT-RT) and cetuximab radiotherapy (cetux-RT) have
been established as the standard of care for the treatment of locally advanced squamous …

5507 Background: The majority of head and neck cancers overexpress the epidermal
growth factor receptor (EGFR), which is associated with aggressive tumor behavior and poor …

Background Previous results from our phase 3 randomised trial showed that adding
cetuximab to primary radiotherapy increased overall survival in patients with locoregionally …